Milestone’s PSVT nasal spray MAA accepted by EMA
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Milestone Pharmaceuticals ( (MIST) ) has issued an announcement.
On January 6, 2026, Milestone Pharmaceuticals announced that the European Medicines Agency has accepted its Marketing Authorization Application for etripamil nasal spray, under the conditionally approved brand name TACHYMIST, for the treatment of paroxysmal supraventricular tachycardia outside the healthcare setting, with a decision on approval expected by the first quarter of 2027. The filing, supported by data from more than 1,800 participants and the pivotal RAPID Phase 3 trial published in 2023, underscores etripamil’s potential to become the first patient self-administered PSVT therapy in Europe, which could significantly reduce emergency visits and invasive procedures for approximately two million European patients and strengthen Milestone’s position in the cardiovascular therapeutics market.
The most recent analyst rating on (MIST) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.
Spark’s Take on MIST Stock
According to Spark, TipRanks’ AI Analyst, MIST is a Neutral.
The score is held down primarily by very weak financial performance (no current revenue, widening losses, and significant cash burn with elevated leverage), reinforced by bearish near-term technicals (price below key short-term moving averages and negative MACD). Valuation provides limited support due to the negative P/E and lack of dividend yield.
To see Spark’s full report on MIST stock, click here.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines for patients with certain heart conditions. Its lead product, CARDAMYST (etripamil) nasal spray, is a novel, self-administered calcium channel blocker approved by the U.S. Food and Drug Administration for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults, and etripamil is also being developed for atrial fibrillation with rapid ventricular rate and pediatric PSVT.
Average Trading Volume: 4,826,969
Technical Sentiment Signal: Hold
Current Market Cap: $172M
Learn more about MIST stock on TipRanks’ Stock Analysis page.
